- Home
- HG vs SRPT Comparison
HG vs SRPT Comparison
Compare HG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | SRPT |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HG | SRPT |
|---|---|---|
| Price | $35.01 | $18.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 24 |
| Target Price | ★ $38.14 | $21.64 |
| AVG Volume (30 Days) | 333.8K | ★ 2.7M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ 51.23 | N/A |
| EPS | 2.73 | ★ 2.99 |
| Revenue | ★ $2,905,524,000.00 | $2,198,237,000.00 |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $12.62 | ★ $6.42 |
| Revenue Growth | ★ 24.70 | 15.58 |
| 52 Week Low | $22.66 | $14.68 |
| 52 Week High | $37.31 | $24.68 |
Technical Indicators
Market Signals| Indicator | HG | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 51.03 |
| Support Level | $33.22 | $18.38 |
| Resistance Level | $36.86 | $20.26 |
| Average True Range (ATR) | 0.97 | 0.96 |
| MACD | -0.14 | 0.20 |
| Stochastic Oscillator | 38.35 | 67.69 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.